0001558370-25-001834 Sample Contracts

EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • February 27th, 2025 • Iovance Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • Maryland

THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of January 10, 2022 by and between Iovance Biotherapeutics, Inc., a Delaware corporation (the “Company”), and Raj K. Puri, M.D., Ph.D. (“Employee”) (either party individually, a “Party”; collectively, the “Parties”).

View SourceView Similar (2)
Contract
Cooperative Research and Development Agreement • February 27th, 2025 • Iovance Biotherapeutics, Inc. • Biological products, (no disgnostic substances)

Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.

View Source
Contract
Cooperative Research and Development Agreement • February 27th, 2025 • Iovance Biotherapeutics, Inc. • Biological products, (no disgnostic substances)

Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.

View Source
SUBLEASE
Sublease • February 27th, 2025 • Iovance Biotherapeutics, Inc. • Biological products, (no disgnostic substances)

THIS SUBLEASE (this “Sublease”) is dated for reference purposes as of November 15, 2024, and is made by and between Vaxcyte, Inc., a Delaware corporation (“Sublessor”), and Iovance Biotherapeutics, Inc., a Delaware corporation (“Sublessee”). Sublessor and Sublessee hereby agree as follows:

View Source
AGREEMENT FOR TERMINATION OF LEASE AND VOLUNTARY SURRENDER OF PREMISES
Agreement for Termination of Lease and Voluntary Surrender of Premises • February 27th, 2025 • Iovance Biotherapeutics, Inc. • Biological products, (no disgnostic substances)

This Agreement for Termination of Lease and Voluntary Surrender of Premises (this “Agreement”) is made and entered into as of November 15, 2024, by and between ARE-SAN FRANCISCO NO. 63, LLC, a Delaware limited liability company (“Landlord”), and IOVANCE BIOTHERAPEUTICS, INC., a Delaware corporation (“Tenant”), with reference to the following:

View Source